Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
DMD Deflationary Engine in High Gear: 7-Day Cumulative Burn Surpasses 34k Tokens

DMD Deflationary Engine in High Gear: 7-Day Cumulative Burn Surpasses 34k Tokens

CointimeCointime2026/04/21 08:26

April 21, 2026 — Driven by the high-frequency execution of the Matrix Prime market-making system, the DMDAO protocol has completed a new round of asset removal today. On-chain monitoring confirms a steady increase in daily burn volume, signaling a total acceleration in the asset's scarcity trajectory.

Core Deflationary Data

Instantaneous Burn (Today): 4,839.41 DMD

7-Day Cumulative Burn: 34,290.36 DMD

Engine Efficiency: [Peak Performance] — Burn frequency is fully synchronized with real-time market-making premiums.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The second wave of energy price increases is looming! European Central Bank’s Lane warns: eurozone inflation will be higher and more persistent

Philip Lane, Chief Economist of the European Central Bank, stated that a new round of high energy prices means inflation in the eurozone will remain elevated for longer than the ECB initially anticipated.

智通财经2026/09/22 07:56

siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions

ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.

智通财经2026/09/22 07:21

Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.

The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.

智通财经2026/09/22 07:11